BASEL, Switzerland, Nov. 1 /PRNewswire/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES).
In the first "Update to Shareholders," we advised shareholders of the Company's new direction as well as the list of licensed products ready to be manufactured and distributed.
Subsequently, we revealed the description of two "Blood Tests" by first releasing a scientific account and analysis followed by a "layman's" version with explanations for common understanding.
We have also informed the public, based on official statistics, of the commercial potential of the SymPath test in the American market.
It is now the time to disclose the work done since the first "Update to Shareholders."
Neuro-Biotech has to date, signed confidentiality agreements with various interested parties, including a Spanish group representing the vast majority of hospitals and private clinics in Spain. This group has shown a particular appreciation for the distribution of all our blood tests. Seeing that there is language and historical ties, all private clinics and private hospitals located in South America will be automatically granted access.
Now if you review the list of licenses your company owns, you will notice that the last four licenses (13, 14, 15, 16), are what we call Neuroceuticals™. It's actually tablets to be sold in pharmacies, that will be classified and sold as "food supplements," in order to accelerate the market penetration. There will be two concentrations; one sold "over the counter," and the other with a medical prescription.
This fact is mentioned due to the ongoing actual negotiations with another Spanish party that controls networks of pharmacies across the country and in South America. Very soon, similar negotiations will open with large chains of pharmacies in the United States and Canada.
We already have on hand a first order from Egypt, and we expect to conclude and receive other sales orders in the near future. The manufacturing of these tablets do not require significant capital investments such as laboratories. Fabrication will be assigned to a pharmaceutical company, already identified, responding to all our criteria and quality standards. As for cost, it remains for us to agree on the quantities to achieve economies of scale.
Regarding our "Blood Tests," we also started preliminary discussions with chains of laboratories, in order to first, identify, evaluate and explore potential partnerships. This will avoid us having to invest in our own lab facilities in the short and medium term while ensuring the production of blood test results for health professionals to track their patients. This is exactly the same principle as a blood test ordered by your doctor to know your cholesterol levels.
We also solicited and were contacted by various insurance companies about "SymPath." This test has been the subject of numerous scientific publications and has been evaluated in over 5,000 human subjects with consistent results of 98.8% precision. With this accuracy, the results could be enough to obtain a legal court opinion on a patient's medical status.
The reason why insurance companies have expressed such a considerable interest is economic. As this test accurately measures the patient's condition on a scale, it avoids the sequences of "trial and error," as is currently the case in the beginning of treatment. Therefore, the health professional receiving the test results will immediately be able to precisely diagnose the patient's condition and to prescribe the proper medication.
The immediate consequences, as you can imagine, will be a dramatic reduction of suffering for the patient, his family, his environment and accelerated healing. From a purely economic and social development standpoint, this will certainly lead to a significant reduction in lost workdays, and fewer payments from insurers and employers! Currently, without this test, it is virtually impossible for medical professional specializing in this type of disease, to separate the real from the fake patients. The whole of society will benefit from this.
The Company will continue to provide its shareholders and investors with timely updates.
For more information, do not hesitate to contact us by using the form on our corporate website at neuro-biotechcorp.com. Your request will be transferred to the appropriate person and we will get back to you as soon as possible. Forward Looking Statements This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
CONTACT: <p>Neuro-Biotech Corp.<br/> Dr Claude Poulin<br/> 41 61 500 05 16<br/> <a href="mailto:firstname.lastname@example.org">email@example.com</a><br/> <a href="http://www.neuro-biotechcorp.com">www.neuro-biotechcorp.com</a></p>
|SOURCE Neuro-Biotech Corp.|
Copyright©2010 PR Newswire.
All rights reserved